- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | NewcelX prices $1.35M equity financing | 1 | Seeking Alpha | ||
| 01.04. | NewcelX sichert sich 1,35 Mio. US-Dollar durch Privatplatzierung mit 30 % Aufschlag | 16 | Investing.com Deutsch | ||
| 01.04. | NewcelX raises $1.35M in private placement at 30% premium | 2 | Investing.com | ||
| 01.04. | NewcelX Ltd.: NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | 3 | GlobeNewswire (USA) | ||
| 10.03. | NewcelX and Eledon partner for NCEL-101 programme | 4 | Pharmaceutical Technology | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 09.03. | NewcelX Enters Strategic Collaboration With Eledon Pharma | - | RTTNews | ||
| 09.03. | NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes | 1 | Contract Pharma | ||
| 09.03. | NewcelX Ltd.: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes | 776 | PR Newswire | Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation
ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq:... ► Artikel lesen | |
| 09.03. | Typ-1-Diabetes: NewcelX und Eledon starten Forschungskooperation | 1 | Investing.com Deutsch | ||
| 09.03. | NewcelX partners with Eledon on type 1 diabetes therapy | 2 | Investing.com | ||
| 09.03. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.02. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.01. | NewcelX Ltd.: NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | 617 | PR Newswire | ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine... ► Artikel lesen | |
| 12.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX: Patent für neurologische Therapien in China veröffentlicht | 4 | Investing.com Deutsch | ||
| 11.12.25 | NewcelX patent for neurological disease treatments published in China | 2 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 86,52 | +4,05 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 35,030 | -1,14 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ARCELLX | 114,80 | +0,01 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 18,050 | +5,31 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| ONCONETIX | 1,210 | +8,04 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson | ||
| AMYLYX PHARMACEUTICALS | 17,320 | +2,30 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 33,520 | +1,51 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| BICARA THERAPEUTICS | 21,980 | +1,76 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | ||
| EVOTEC | 4,526 | -3,21 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,620 | +6,37 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| COGENT BIOSCIENCES | 37,330 | +1,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| IMMUNOVANT | 25,650 | +3,72 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 15,210 | +1,64 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| ERASCA | 17,360 | +2,48 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,940 | +1,44 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen |
NEWCELX LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,110 Euro und damit -2,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.